FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerThe FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung Share XFDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerhttps://pharmaphorum.com/news/fda-grants-fast-review-for-astrazenecas-tagrisso-in-early-stage-lung-cancer/
New data reinforce Keytruda’s dominance in first-line lung cancerFive-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off Share XNew data reinforce Keytruda’s dominance in first-line lung cancerhttps://pharmaphorum.com/news/new-data-reinforce-keytrudas-dominance-in-first-line-lung-cancer/
Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerUK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell Share XPrice cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerhttps://pharmaphorum.com/news/price-cut-wins-nice-ok-for-azs-tagrisso-in-untreated-lung-cancer/
FDA starts quick review of Merck’s MET-targeting lung cancer drugMerck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer Share XFDA starts quick review of Merck’s MET-targeting lung cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/
Latecomer Lilly throws cash at Innovent PD-1 partnershipEli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights Share XLatecomer Lilly throws cash at Innovent PD-1 partnershiphttps://pharmaphorum.com/news/latecomer-lilly-throws-cash-at-innovent-pd-1-partnership/
Will new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug Share XWill new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?https://pharmaphorum.com/news/will-new-data-make-pfizers-lorbrena-a-no-brainer-in-early-lung-cancer/
Given after surgery, AZ’s Tagrisso prevents lung cancer coming backAstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Share XGiven after surgery, AZ’s Tagrisso prevents lung cancer coming backhttps://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/
BMS eyes August FDA verdict for Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb is trying again to get approval for its checkpoint inhibitor combination of Opdivo and Yervoy in Share XBMS eyes August FDA verdict for Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-eyes-august-fda-verdict-for-opdivo-yervoy-in-first-line-lung-cancer/
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdictEli Lilly’s cancer drug Cyramza has inched closer to a new indication in first-line non-small cell lung cancer Share XLilly’s Cyramza closer to first-line lung cancer use after ODAC verdicthttps://pharmaphorum.com/news/lilly-closes-on-first-line-lung-cancer-use-after-odac-verdict/
